Armistice Capital’s Achillion Pharmaceuticals ACHN Stock Holding History

Armistice Capital’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,500,000	Closed	-$7.4M	–	89
2019 Q1	$7.4M	Sell	2,500,000 -1,800,000	-42%	-$4.42M	0.41%	46
2018 Q4	$6.84M	Buy	4,300,000 +2,300,000	+115%	+$6.5M	0.52%	39
2018 Q3	$7.36M	Sell	2,000,000 -2,000,000	-50%	-$5.96M	0.44%	52
2018 Q2	$11.3M	Sell	4,000,000 -296,000	-7%	-$1.01M	0.74%	43
2018 Q1	$15.9M	Buy	+4,296,000	New	+$14.1M	1.22%	33
2017 Q4	–	Sell	-1,020,000	Closed	-$4.58M	–	88
2017 Q3	$4.58M	Buy	+1,020,000	New	+$4.53M	0.54%	50

Other funds holding ACHN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Armistice Capital's ACHN Position: Q2 2019 in Review

Armistice Capital sold out of Achillion Pharmaceuticals (ACHN) in Q2 2019, closing a stake of 2,500,000 shares — an estimated $7.4M sold.

Armistice Capital first reported a position in ACHN in Q3 2017 and held it in 6 quarters. The position peaked at $15.9M in Q1 2018. 114 funds tracked by Wall St. Rank hold ACHN as of Q2 2019.

Armistice Capital reported no remaining Achillion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Armistice Capital sold 2,500,000 Achillion Pharmaceuticals shares in Q2 2019, an estimated $7.4M.
Armistice Capital first reported a position in Achillion Pharmaceuticals in Q3 2017 and held it in 6 quarters.
Armistice Capital's Achillion Pharmaceuticals position peaked at $15.9M in Q1 2018.
114 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2019.

Based on Armistice Capital's 13F filing for Q2 2019, filed 14 Aug 2019.